Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 7, keine Gesamtzahl für „baseline“
Suchtreffer
Begriffe & Kennungen
Olanzapine Glenmark · 4.8 · mmol/l) and changes in fasting triglycerides from borderline at baseline (≥ 1.016 mmol/l - < 1.467 mmol/l) to
Eintrag öffnenOlanzapine Glenmark · 4.8 · mmol/l) and changes in fasting triglycerides from borderline at baseline (≥ 1.016 mmol/l - < 1.467 mmol/l) to
Eintrag öffnenOlanzapine Glenmark · 4.8 · mmol/l) and changes in fasting triglycerides from borderline at baseline (≥ 1.016 mmol/l - < 1.467 mmol/l) to
Eintrag öffnenOlanzapine Teva · 4.8 · 10 4 Observed for fasting normal levels at baseline (<5.56 mmol/l) which increased to high (≥7 mmol/l). Change
Eintrag öffnenOlanzapine Teva · 4.8 · 11 bipolar disorder was associated with an increase of ≥7% from baseline body weight in 39.9% of patients.
Eintrag öffnenOlanzapine Teva · 4.8 · 28 3 Observed for fasting normal levels at baseline (<5.17 mmol/l) which increased to high (≥6.2 mmol/l). Chan
Eintrag öffnenOlanzapine Viatris (previously Olanzapine Mylan) · 4.8 · 1 Clinically significant weight gain was observed across all baseline Body Mass Index (BMI) categories. Follow
Eintrag öffnenOlanzapine Viatris (previously Olanzapine Mylan) · 4.8 · 10 3 Observed for fasting normal levels at baseline (< 5.17 mmol/l) which increased to high (≥ 6.2 mmol/l). Ch
Eintrag öffnenOlazax Disperzi · 4.8 · 1 Clinically significant weight gain was observed across all baseline Body Mass Index (BMI) categories. Follow
Eintrag öffnenOlazax Disperzi · 4.8 · 1 Clinically significant weight gain was observed across all baseline Body Mass Index (BMI) categories. Follow
Eintrag öffnenOlazax Disperzi · 4.8 · 1 Clinically significant weight gain was observed across all baseline Body Mass Index (BMI) categories. Follow
Eintrag öffnenOlazax Disperzi · 4.8 · 13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) wa
Eintrag öffnenOlazax Disperzi · 4.8 · 13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) wa
Eintrag öffnenOlazax Disperzi · 4.8 · 13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) wa
Eintrag öffnenOlazax Disperzi · 4.8 · 13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) wa
Eintrag öffnenOlazax · 4.8 · 1 Clinically significant weight gain was observed across all baseline Body Mass Index (BMI) categories. Follow
Eintrag öffnenOlazax · 4.8 · 1 Clinically significant weight gain was observed across all baseline Body Mass Index (BMI) categories. Follow
Eintrag öffnenOlazax · 4.8 · 1 Clinically significant weight gain was observed across all baseline Body Mass Index (BMI) categories. Follow
Eintrag öffnenOlazax · 4.8 · 1 Clinically significant weight gain was observed across all baseline Body Mass Index (BMI) categories. Follow
Eintrag öffnenOlazax · 4.8 · 13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) wa
Eintrag öffnen